Association of variations in HLA class II and other loci with susceptibility to EGFR-mutated lung adenocarcinoma
Shiraishi, Kouya (National Cancer Center Research Institute (Tòquio, Japó))
Okada, Yukinori (Tokyo Medical and Dental University)
Takahashi, Atsushi (RIKEN Center for Integrative Medical Sciences (Yokohama, Japó))
Kamatani, Yoichiro (RIKEN Center for Integrative Medical Sciences (Yokohama, Japó))
Momozawa, Yukihide (RIKEN Center for Integrative Medical Sciences (Yokohama, Japó))
Ashikawa, Kyota (RIKEN Center for Integrative Medical Sciences (Yokohama, Japó))
Kunitoh, Hideo (Japanese Red Cross Medical Center (Tòquio, Japó))
Matsumoto, Shingo (National Cancer Center Research Institute (Tòquio, Japó))
Takano, Atsushi (The University of Tokyo)
Shimizu, Kimihiro (Gunma University Hospital (Maebashi, Japó))
Goto, Akiteru (Akita University (Akita, Japó))
Tsuta, Koji (National Cancer Center Hospital (Tòquio, Japó))
Watanabe, Shun-ichi (National Cancer Center Hospital (Tòquio, Japó))
Ohe, Yuichiro (National Cancer Center Hospital (Tòquio, Japó))
Watanabe, Yukio (National Cancer Center Hospital (Tòquio, Japó))
Goto, Yasushi (National Cancer Center Hospital (Tòquio, Japó))
Nokihara, Hiroshi (National Cancer Center Hospital (Tòquio, Japó))
Furuta, Koh (National Cancer Center Hospital (Tòquio, Japó))
Yoshida, Akihiko (National Cancer Center Hospital (Tòquio, Japó))
Goto, Koichi (National Cancer Center Hospital East (Chiba, Japó))
Hishida, Tomoyuki (National Cancer Center Hospital East (Chiba, Japó))
Tsuboi, Masahiro (National Cancer Center Hospital East (Chiba, Japó))
Tsuchihara, Katsuya (National Cancer Center Research Institute (Tòquio, Japó))
Miyagi, Yohei (Kanagawa Cancer Center Research Institute (Yokohama, Japó))
Nakayama, Haruhiko (Kanagawa Cancer Center (Yokohama, Japó))
Yokose, Tomoyuki (Kanagawa Cancer Center (Yokohama, Japó))
Tanaka, Kazumi (Gunma University Hospital (Maebashi, Japó))
Nagashima, Toshiteru (Gunma University Hospital (Maebashi, Japó))
Ohtaki, Yoichi (Gunma University Hospital (Maebashi, Japó))
Maeda, Daichi (Akita University (Akita, Japó))
Imai, Kazuhiro (Akita University (Akita, Japó))
Minamiya, Yoshihiro (Akita University (Akita, Japó))
Sakamoto, Hiromi (National Cancer Center Research Institute (Tòquio, Japó))
Saito, Akira (StaGen Co., Ltd. (Tòquio, Japó))
Shimada, Yoko (National Cancer Center Research Institute (Tòquio, Japó))
Sunami, Kuniko (National Cancer Center Research Institute (Tòquio, Japó))
Saito, Motonobu (National Cancer Center Research Institute (Tòquio, Japó))
Inazawa, Johji (Tokyo Medical and Dental University)
Nakamura, Yusuke (University of Chicago)
Yoshida, Teruhiko (National Cancer Center Research Institute (Tòquio, Japó))
Yokota, Jun (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer)
Matsuda, Fumihiko (Kyoto University)
Matsuo, Keitaro (Aichi Cancer Center Research Institute (Nagoya, Japó))
Daigo, Yataro (The University of Tokyo)
Kubo, Michiaki (RIKEN Center for Integrative Medical Sciences (Yokohama, Japó))
Kohno, Takashi (National Cancer Center Research Institute (Tòquio, Japó))

Date:	2016
Abstract:	Lung adenocarcinoma driven by somatic EGFR mutations is more prevalent in East Asians (30-50%) than in European/Americans (10-20%). Here we investigate genetic factors underlying the risk of this disease by conducting a genome-wide association study, followed by two validation studies, in 3,173 Japanese patients with EGFR mutation-positive lung adenocarcinoma and 15,158 controls. Four loci, 5p15. 33 (TERT), 6p21. 3 (BTNL2), 3q28 (TP63) and 17q24. 2 (BPTF), previously shown to be strongly associated with overall lung adenocarcinoma risk in East Asians, were re-discovered as loci associated with a higher susceptibility to EGFR mutation-positive lung adenocarcinoma. In addition, two additional loci, HLA class II at 6p21. 32 (rs2179920; P =5. 1 × 10(-17), per-allele OR=1. 36) and 6p21. 1 (FOXP4) (rs2495239; P=3. 9 × 10(-9), per-allele OR=1. 19) were newly identified as loci associated with EGFR mutation-positive lung adenocarcinoma. This study indicates that multiple genetic factors underlie the risk of lung adenocarcinomas with EGFR mutations.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Published in:	Nature communications, Vol. 7 (August 2016) , art. 12451, ISSN 2041-1723

DOI: 10.1038/ncomms12451
PMID: 27501781

7 p, 525.4 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Research articles
Articles > Published articles